Lawal, B.; Liu, Y.-L.; Mokgautsi, N.; Khedkar, H.; Sumitra, M.R.; Wu, A.T.H.; Huang, H.-S.
Pharmacoinformatics and Preclinical Studies of NSC765690 and NSC765599, Potential STAT3/CDK2/4/6 Inhibitors with Antitumor Activities against NCI60 Human Tumor Cell Lines. Biomedicines 2021, 9, 92.
https://doi.org/10.3390/biomedicines9010092
AMA Style
Lawal B, Liu Y-L, Mokgautsi N, Khedkar H, Sumitra MR, Wu ATH, Huang H-S.
Pharmacoinformatics and Preclinical Studies of NSC765690 and NSC765599, Potential STAT3/CDK2/4/6 Inhibitors with Antitumor Activities against NCI60 Human Tumor Cell Lines. Biomedicines. 2021; 9(1):92.
https://doi.org/10.3390/biomedicines9010092
Chicago/Turabian Style
Lawal, Bashir, Yen-Lin Liu, Ntlotlang Mokgautsi, Harshita Khedkar, Maryam Rachmawati Sumitra, Alexander T. H. Wu, and Hsu-Shan Huang.
2021. "Pharmacoinformatics and Preclinical Studies of NSC765690 and NSC765599, Potential STAT3/CDK2/4/6 Inhibitors with Antitumor Activities against NCI60 Human Tumor Cell Lines" Biomedicines 9, no. 1: 92.
https://doi.org/10.3390/biomedicines9010092
APA Style
Lawal, B., Liu, Y.-L., Mokgautsi, N., Khedkar, H., Sumitra, M. R., Wu, A. T. H., & Huang, H.-S.
(2021). Pharmacoinformatics and Preclinical Studies of NSC765690 and NSC765599, Potential STAT3/CDK2/4/6 Inhibitors with Antitumor Activities against NCI60 Human Tumor Cell Lines. Biomedicines, 9(1), 92.
https://doi.org/10.3390/biomedicines9010092